{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,11]],"date-time":"2024-02-11T14:41:26Z","timestamp":1707662486369},"reference-count":31,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2007,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>The surrogate of protection against<jats:italic>Neisseria meningitidis<\/jats:italic>serogroup B (MenB) is the serum bactericidal antibody (SBA) assay, which measures the functional activity of antibody by using an exogenous complement source. Despite baby rabbit complement having been used in meningococcal serogroup A, C, Y, and W135 SBA assays, it is not recommended for use in the MenB SBA assay due to elevated SBA titers caused by low-avidity anti-MenB capsular antibody in test sera. Therefore, the possibility of absorbing anti-MenB capsular antibody from test sera to enable the use of baby rabbit complement in the MenB SBA assay was investigated by comparing the results with those gained using human complement. Colominic acid from<jats:italic>Escherichia coli<\/jats:italic>K1, which shares the same linkage residue as MenB polysaccharide, was used as an absorbent due to the commercial unavailability of purified MenB polysaccharide. Inclusion of soluble colominic acid as an absorbent with baby rabbit complement resulted in a general reduction in SBA titers compared with those obtained using baby rabbit complement alone. However, these were not comparable to human SBA titers for all samples. Further optimization and investigations demonstrated that for some samples, colominic acid reduced titers to less than those achieved with human complement, and for others, it was not possible to inhibit titers by using colominic acid. The results suggested that the use of colominic acid will not result in the ability to use baby rabbit complement in the MenB SBA assay, thus not alleviating the difficulties in procuring human complement. However, alternative absorbents, such as purified MenB polysaccharide, may warrant further evaluation.<\/jats:p>","DOI":"10.1128\/cvi.00452-06","type":"journal-article","created":{"date-parts":[[2007,3,8]],"date-time":"2007-03-08T04:32:35Z","timestamp":1173328355000},"page":"556-561","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":1,"title":["Inadequacy of Colominic Acid as an Absorbent Intended To Facilitate Use of Complement-Preserved Baby Rabbit Serum in the<i>Neisseria meningitidis<\/i>Serogroup B Serum Bactericidal Antibody Assay"],"prefix":"10.1128","volume":"14","author":[{"given":"Jamie","family":"Findlow","sequence":"first","affiliation":[{"name":"Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, P.O. Box 209, Clinical Sciences Building II, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom"},{"name":"Institute of Environmental Science &amp; Research Ltd., Kenepuru Science Centre, Porirua, New Zealand"},{"name":"Novartis Vaccines, Via Fiorentina 1, 53100 Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Holland","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, P.O. Box 209, Clinical Sciences Building II, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom"},{"name":"Institute of Environmental Science &amp; Research Ltd., Kenepuru Science Centre, Porirua, New Zealand"},{"name":"Novartis Vaccines, Via Fiorentina 1, 53100 Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Martin","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, P.O. Box 209, Clinical Sciences Building II, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom"},{"name":"Institute of Environmental Science &amp; Research Ltd., Kenepuru Science Centre, Porirua, New Zealand"},{"name":"Novartis Vaccines, Via Fiorentina 1, 53100 Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Oster","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, P.O. Box 209, Clinical Sciences Building II, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom"},{"name":"Institute of Environmental Science &amp; Research Ltd., Kenepuru Science Centre, Porirua, New Zealand"},{"name":"Novartis Vaccines, Via Fiorentina 1, 53100 Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Balmer","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, P.O. Box 209, Clinical Sciences Building II, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom"},{"name":"Institute of Environmental Science &amp; Research Ltd., Kenepuru Science Centre, Porirua, New Zealand"},{"name":"Novartis Vaccines, Via Fiorentina 1, 53100 Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, P.O. Box 209, Clinical Sciences Building II, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom"},{"name":"Institute of Environmental Science &amp; Research Ltd., Kenepuru Science Centre, Porirua, New Zealand"},{"name":"Novartis Vaccines, Via Fiorentina 1, 53100 Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.63.5.1906-1913.1995"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.4049\/jimmunol.160.7.3342","volume":"160","year":"1998","unstructured":"Blackmore, T. K., J. Hellwage, T. A. Sadlon, N. Higgs, P. F. Zipfel, H. M. Ward, and D. L. Gordon. 1998. Identification of the second heparin-binding domain in human complement factor H. J. Immunol.160:3342-3348.","journal-title":"J. Immunol."},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.4049\/jimmunol.157.12.5422","volume":"157","year":"1996","unstructured":"Blackmore, T. K., T. A. Sadlon, H. M. Ward, D. M. Lublin, and D. L. Gordon. 1996. Identification of a heparin binding domain in the seventh short consensus repeat of complement factor H. J. Immunol.157:5422-5427.","journal-title":"J. Immunol."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1128\/CDLI.12.8.970-976.2005","volume":"12","year":"2005","unstructured":"Borrow, R., I. S. Aaberge, G. F. Santos, T. L. Eudey, P. Oster, A. Glennie, J. Findlow, E. A. H\u00f8iby, E. Rosenqvist, P. Balmer, and D. Martin. 2005. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup B, strain 44\/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin. Diagn. Lab. Immunol.12:970-976.","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1016\/j.vaccine.2006.03.091","volume":"24","year":"2006","unstructured":"Borrow, R., G. M. Carlone, N. Rosenstein, M. Blake, I. Feavers, D. Martin, W. Zollinger, J. Robbins, I. S. Aaberge, D. M. Granoff, E. Miller, B. Plikaytis, L. van Alphen, J. Poolman, R. Rappuoli, L. Danzig, J. Hackell, B. Danve, M. Caulfield, S. Lambert, and D. Stephens. 2006. Neisseria meningitidis group B correlates of protection and assay standardization. Vaccine24:5093-5107.","journal-title":"Vaccine"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/0264-410X(94)00037-N","volume":"13","year":"1995","unstructured":"Boslego, J., J. Garcia, C. Cruz, W. Zollinger, B. Brandt, S. Ruiz, M. Martinez, J. Arthur, P. Underwood, W. Silva, E. Moran, W. Hankins, J. Gilly, P. Mays, and The Chilean National Committee for Meningococcal Disease. 1995. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Vaccine13:821-829.","journal-title":"Vaccine"},{"key":"e_1_3_2_8_2","first-page":"355","year":"1983","unstructured":"Finne, J., M. Leinonen, and P. H. M\u00e4kel\u00e4. 1983. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancetii:355-357.","journal-title":"Lancet"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","volume":"129","year":"1969","unstructured":"Goldschneider, I., E. C. Gotschlich, and M. S. Artenstein. 1969. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med.129:1307-1326.","journal-title":"J. Exp. Med."},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1084\/jem.129.6.1327","volume":"129","year":"1969","unstructured":"Goldschneider, I., E. C. Gotschilch, and M. S. Artenstein. 1969. Human immunity to the meningococcus. II. Development of natural immunity. J. Exp. Med.129:1327-1348.","journal-title":"J. Exp. Med."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/cdli.2.5.574-582.1995"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0161-5890(89)90003-5","volume":"26","year":"1989","unstructured":"Hayrinen, J., D. Bitter-Suermann, and J. Finne. 1989. Interaction of meningococcal group B monoclonal antibody and its Fab fragment with alpha 2-8-linked sialic acid polymers: requirement of a long oligosaccharide segment for binding. Mol. Immunol.26:523-529.","journal-title":"Mol. Immunol."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/infdis\/171.6.1481","volume":"171","year":"1995","unstructured":"Hayrinen, J., H. Jennings, H. V. Raff, G. Rougon, N. Hanai, R. Gerardy-Schahn, and J. Finne. 1995. Antibodies to polysialic acid and its N-propyl derivative: binding properties and interaction with human embryonal brain glycopeptides. J. Infect. Dis.171:1481-1490.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0161-5890(02)00202-X","volume":"39","year":"2002","unstructured":"Hayrinen, J., S. Haseley, P. Talaga, M. Muhlenhoff, J. Finne, and J. F. Vliegenthart. 2002. High affinity binding of a long-chain polysialic acid to antibody, and modulation by divalent cations and polyamines. Mol. Immunol.39:399-411.","journal-title":"Mol. Immunol."},{"key":"e_1_3_2_15_2","unstructured":"The use of non-human complement sources in the serogroup B Neisseria meningitidis serum bactericidal assay facilitated by a colominic acid absorbent 2002"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0264-410X(02)00591-1","volume":"21","year":"2003","unstructured":"Holst, J., B. Feiring, J. E. Fuglesang, E. A. H\u00f8iby, H. N\u00f8kleby, I. S. Aaberge, and E. Rosenqvist. 2003. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine21:734-737.","journal-title":"Vaccine"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.4049\/jimmunol.134.4.2651","volume":"134","year":"1985","unstructured":"Jennings, H. J., R. Roy, and F. Michon. 1985. Determinant specificities of the groups B and C polysaccharides of Neisseria meningitidis. J. Immunol.134:2651-2657.","journal-title":"J. Immunol."},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1574-695X.2006.00121.x","volume":"48","year":"2006","unstructured":"Laher, G., P. Balmer, S. J. Gray, M. Dawson, E. B. Kaczmarski, and R. Borrow. 2006. Development and evaluation of a rapid multianalyte particle-based flow cytometric assay for the quantification of meningococcal serogroup B-specific IgM antibodies in sera for non-culture case confirmation. FEMS Immunol. Med. Microbiol.48:34-43.","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1093\/infdis\/154.6.1033","volume":"154","year":"1986","unstructured":"Lepow, M. L., J. Beeler, M. Randolph, J. S. Samuelson, and W. A. Hankins. 1986. Reactogenicity and immunogenicity of a quadrivalent combined meningococcal polysaccharide vaccine in children. J. Infect. Dis.154:1033-1036.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0008-6215(84)85040-5","volume":"134","year":"1984","unstructured":"Lifely, M. R., A. S. Gilbert, and C. Moreno. 1984. Rate, mechanism, and immunochemical studies of lactonisation in serogroup B and C polysaccharides of Neisseria meningitidis. Carbohydr. Res.134:229-243.","journal-title":"Carbohydr. Res."},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4049\/jimmunol.177.1.501","volume":"177","year":"2006","unstructured":"Madico, G., J. A. Welsch, L. A. Lewis, A. McNaughton, D. H. Perlman, C. E. Costello, J. Ngampsutado, U. Vogel, D. M. Granoff, and S. Ram. 2006. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J. Immunol.177:501-510.","journal-title":"J. Immunol."},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/infdis\/172.5.1279","volume":"172","year":"1995","unstructured":"Mandrell, R. E., F. H. Azmi, and D. M. Granoff. 1995. Complement mediated bactericidal activity of human antibodies to poly alpha 2\u21928 N-acetylneuraminic acid, the capsular polysaccharide of Neisseria meningitidis serogroup B. J. Infect. Dis.172:1279-1289.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.vaccine.2005.01.070","volume":"23","year":"2005","unstructured":"Martin, D., L. McCallum, A. Glennie, N. Ruijne, P. Blatchford, J. O'Hallahan, and P. Oster. 2005. Validation of the serum bactericidal assay for measurement of functional antibodies against group B meningococci associated with vaccine trials. Vaccine23:2218-2221.","journal-title":"Vaccine"},{"key":"e_1_3_2_24_2","first-page":"156","volume":"4","year":"1997","unstructured":"Maslanka, S. E., L. L. Gheesling, D. E. Libutti, K. B. J. Donaldson, H. S. Harakeh, J. K. Dykes, F. F. Arhin, S. J. N. Devi, C. E. Frasch, J. C. Huang, P. Kriz-Kuzemenska, R. D. Lemmon, M. Lorange, C. C. A. M. Peeters, S. Quataert, J. Y. Tai, G. M. Carlone, and The Multilaboratory Study Group. 1997. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. J. Clin. Microbiol.4:156-167.","journal-title":"J. Clin. Microbiol."},{"key":"e_1_3_2_25_2","unstructured":"A novel interaction between factor H SCR 6 and the meningococcal vaccine candidate GNA1870: implications for meningococcal pathogenesis and vaccine development 2006"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"17142","DOI":"10.1073\/pnas.0506471102","volume":"102","year":"2005","unstructured":"Ngampasutadol, J., S. Ram, A. M. Blom, H. Jarva, A. E. Jerse, E. Lien, J. Goguen, S. Gulati, and P. A. Rice. 2005. Human C4b-binding protein selectively interacts with Neisseria gonorrhoeae and results in species-specific infection. Proc. Natl. Acad. Sci. USA102:17142-17147.","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.vaccine.2005.01.063","volume":"23","year":"2005","unstructured":"Oster, P., D. Lennon, J. O'Hallahan, K. Mulholland, S. Reid, and D. Martin. 2005. MeNZB\u2122: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine23:2191-2196.","journal-title":"Vaccine"},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"7566","DOI":"10.4049\/jimmunol.176.12.7566","volume":"176","year":"2006","unstructured":"Schneider, M. C., R. M. Exley, H. Chan, I. Feavers, Y. H. Kang, R. B. Sim, and C. M. Tang. 2006. Functional significance of factor H binding to Neisseria meningitidis. J. Immunol.176:7566-7575.","journal-title":"J. Immunol."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.10.4.514-519.2003"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/infdis\/126.5.514","volume":"126","year":"1972","unstructured":"Wyle, F. A., M. S. Artenstein, B. L. Brandt, E. C. Tramont, D. L. Kasper, P. L. Altieri, S. L. Berman, and J. P. Lowenthal. 1972. Immunological response of man to group B meningococcal polysaccharide antigens. J. Infect. Dis.126:514-522.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.40.1.257-264.1983"},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1128\/IAI.65.3.1053-1060.1997","volume":"65","year":"1997","unstructured":"Zollinger, W., E. Moran, S. Devi, and C. Frasch. 1997. Bactericidal antibody responses of rhesus monkeys immunized with group B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines. Infect. Immun.65:1053-1060.","journal-title":"Infect. Immun."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00452-06","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00452-06","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,11]],"date-time":"2024-02-11T14:17:57Z","timestamp":1707661077000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00452-06"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["10.1128\/CVI.00452-06"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00452-06","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5]]},"assertion":[{"value":"2006-12-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2007-02-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}